Janssen-cilag G.m.b.h

This study follows 400 people with Crohn's disease or ulcerative colitis who are starting treatment with guselkumab in real-world medical settings. The main goal is to see how well the drug controls symptoms like abdominal pain, diarrhea, and rectal bleeding, and to measure its i…